Hikma Specialty USA Inc.

Hikma Specialty USA Inc., a foreign-owned pharmaceutical manufacturer based in Columbus, Ohio, supplies generic injectable and non-injectable drugs, pharmaceuticals, and hematology-related products to federal healthcare systems as a prime contractor on a GSA Federal Supply Schedule vehicle (21% of recent awards) and as a sub-recipient on federal grants from state health agencies (79% of recent awards). The vendor holds no SBA set-aside designations and competes full-and-open across both prime and sub channels.

Hikma's federal footprint centers on two distinct channels. On the prime side, the vendor holds a multiple-award Federal Supply Schedule contract under Pharmaceuticals and Drugs (FSS-61-IB) awarded June 1, 2022, with a ceiling of $1,250,080 extending through May 31, 2027, serving the Department of Veterans Affairs Veterans Integrated Service Network 12 with task orders for pharmaceutical inventory to VA medical centers. This vehicle accounts for all three prime awards ($10 million combined potential value) in the recent footprint. On the sub-recipient side, Hikma delivers pharmaceutical products under ten federal grant sub-awards from the Tennessee Department of Mental Health and Substance Abuse Services, the prime recipient of federal mental health and substance abuse grants. Notable sub-awards include a September 2025 sub for supply of Kloxxado (naloxone nasal spray) in two 8 milligram doses to an indigent population with twenty-four-hour order fulfillment and two-day shipping, and a January 2024 naloxone sub-award under COVID-19 supplemental funding to ensure access to overdose-reversal medication for individuals leaving treatment facilities or deemed high-risk. The vendor also holds sub-awards from the Department of Justice Office of Justice Programs Bureau of Justice Assistance, though the source does not detail those scope descriptions.

Customer concentration is heavily weighted toward the Veterans Affairs Veterans Integrated Service Network 12 on the potential-value axis ($10 million) and the Department of Health and Human Services Substance Abuse and Mental Health Services Administration on the award-count axis (eight awards across two fiscal lines). The Department of Justice accounts for three sub-awards. Activity accelerated in 2024 (seven awards) after sparse prior volume, with three awards in 2025 and one in 2026 year-to-date. The vendor's award distribution heavily favors the sub-recipient role, reflecting Hikma's position as a pharmaceutical supplier to state agencies receiving federal mental health and substance abuse grant funding rather than as a direct federal customer. The primary NAICS category is Pharmaceutical Preparation Manufacturing, with Drugs and Biologicals as the top PSC.